down arrow

MEI Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US55279B3015
USD
1.39
0.02 (1.46%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.331.39

52 Week

1.339.00
Valuation
Technical
Day's Volume

CASH

658.83 k

Shareholding (Mar 2025)

FII

1.13%

Held by 8 FIIs

DII

91.55%

Held by 8 DIIs

Promoter

0.00%

How big is MEI Pharma, Inc.?

22-Jun-2025

As of Jun 18, MEI Pharma, Inc. has a market capitalization of 14.99 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -31.67 million for the latest four quarters. The company reported shareholder's funds of 33.02 million and total assets of 41.38 million as of Jun'24.

Market Cap: As of Jun 18, MEI Pharma, Inc. has a market capitalization of 14.99 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, MEI Pharma, Inc. reported net sales of 0.00 million and a net profit of -31.67 million.<BR><BR>Balance Sheet Snapshot: As of Jun'24, the company reported shareholder's funds of 33.02 million and total assets of 41.38 million.

Read More

What does MEI Pharma, Inc. do?

22-Jun-2025

MEI Pharma, Inc. is an oncology company focused on developing cancer treatments, categorized as a micro-cap with a market cap of $14.99 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

Overview:<BR>MEI Pharma, Inc. is an oncology company focused on the clinical development of drugs and therapies for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 14.99 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.05<BR>Return on Equity: -106.26%<BR>Price to Book: 0.77<BR><BR>Contact Details:<BR>Address: 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO CA: 92130<BR>Tel: 1 858 3697100<BR>Website: https://www.meipharma.com/

Read More

Who are in the management team of MEI Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of MEI Pharma, Inc. includes Dr. Christine White (Independent Chairman), Dr. Daniel Gold (President and CEO), and five Independent Directors: Mr. Charles Baltic, Dr. Kevan Clemens, Ms. Cheryl Cohen, and Mr. Frederick Driscoll.

As of March 2022, the management team of MEI Pharma, Inc. includes the following individuals:<BR><BR>- Dr. Christine White, who serves as the Independent Chairman of the Board.<BR>- Dr. Daniel Gold, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Charles Baltic, who is an Independent Director.<BR>- Dr. Kevan Clemens, who is also an Independent Director.<BR>- Ms. Cheryl Cohen, who serves as an Independent Director.<BR>- Mr. Frederick Driscoll, who is an Independent Director.<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is MEI Pharma, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, MEI Pharma, Inc. is considered overvalued with poor financial metrics, including a Price to Book Value of 0.74, an EV to EBITDA ratio of 0.27, a ROE of -106.26%, and significant underperformance compared to the S&P 500, making it a less attractive investment.

As of 8 July 2024, MEI Pharma, Inc. has moved from a very attractive valuation grade to one that does not qualify. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.74 and an EV to EBITDA ratio of 0.27, which indicate a lack of profitability and efficiency in generating earnings relative to its enterprise value. Additionally, the ROE stands at -106.26%, highlighting significant losses relative to shareholder equity.<BR><BR>In comparison to its peers, MEI Pharma, Inc. shows a less favorable position, with Immunic, Inc. having a P/E ratio of -0.8008 and Adicet Bio, Inc. at -0.5353, suggesting that while all companies are struggling, MEI's valuation metrics are particularly concerning. The stock has underperformed significantly against the S&P 500, with a 1Y return of -10.86% compared to the index's 17.14%, and a staggering -96.17% over the last 5 years, reinforcing the notion that the company is not a viable investment at its current price.

Read More

Is MEI Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, MEI Pharma, Inc. has a mildly bullish technical trend, supported by daily moving averages and KST momentum, but tempered by bearish Bollinger Bands and mixed MACD signals, while significantly underperforming the S&P 500 over the past three years.

As of 4 September 2025, the technical trend for MEI Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, which supports the overall mildly bullish stance. However, the Bollinger Bands are bearish on both weekly and monthly time frames, suggesting potential downward pressure. The KST shows bullish momentum on both weekly and monthly charts, and the OBV is bullish on a monthly basis, indicating accumulation. <BR><BR>In terms of performance, MEI Pharma has underperformed the S&P 500 across multiple periods, with a significant decline of 72.90% over the last 3 years compared to a 70.41% gain in the S&P 500. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators in the Bollinger Bands and mixed MACD signals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 99 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-106.26%

stock-summary
Price to Book

5.04

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.52%
0%
-48.52%
6 Months
-38.63%
0%
-38.63%
1 Year
-41.1%
0%
-41.1%
2 Years
-77.72%
0%
-77.72%
3 Years
456.0%
0%
456.0%
4 Years
-97.3%
0%
-97.3%
5 Years
-97.6%
0%
-97.6%

MEI Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
8.97%
EBIT to Interest (avg)
-30.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
1.50
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
53.74%
ROCE (avg)
0
ROE (avg)
10.25%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
0.26
EV to EBITDA
0.27
EV to Capital Employed
5.94
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2265.80%
ROE (Latest)
-106.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (7.32%)

Foreign Institutions

Held by 8 Foreign Institutions (1.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 3.70% vs 66.25% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-3.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.60",
          "val2": "-2.70",
          "chgp": "3.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 33.81% vs 19.90% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 155.97% vs 41.65% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65.30",
          "val2": "48.80",
          "chgp": "33.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25.80",
          "val2": "-31.30",
          "chgp": "182.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.90",
          "val2": "-2.00",
          "chgp": "-445.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.80",
          "val2": "-31.80",
          "chgp": "155.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "389.60%",
          "val2": "-679.40%",
          "chgp": "106.90%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.80
-3.50
20.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.60
-2.70
3.70%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 3.70% vs 66.25% in Dec 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
65.30
48.80
33.81%
Operating Profit (PBDIT) excl Other Income
25.80
-31.30
182.43%
Interest
0.00
0.00
Exceptional Items
-10.90
-2.00
-445.00%
Consolidate Net Profit
17.80
-31.80
155.97%
Operating Profit Margin (Excl OI)
389.60%
-679.40%
106.90%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is 33.81% vs 19.90% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 155.97% vs 41.65% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About MEI Pharma, Inc. stock-summary
stock-summary
MEI Pharma, Inc.
Pharmaceuticals & Biotechnology
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Company Coordinates stock-summary
Company Details
11455 EL CAMINO REAL, SUITE 250 , SAN DIEGO CA : 92130
stock-summary
Tel: 1 858 3697100
stock-summary
https://www.meipharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."